Eli Lilly’s Foundayo meets main goal in late-stage sleep apnea trial

The read-through here is less about sleep apnea than about the broadening clinical case for oral GLP-1-class therapy: a positive late-stage result in a respiratory condition extends the drug's potential label beyond weight loss itself. That matters for Lilly's competitive positioning against other oral obesity candidates, and for payers weighing coverage of a condition with a clear diagnostic measure. The 52-week endpoint and the magnitude of the reduction are the details clinicians will scrutinize. Whether regulators treat sleep apnea as a distinct indication, and how that shapes pricing and access, is the open question.